|
1
|
Whitcomb BP: Gynecologic malignancies.
Surg Clin North Am. 88:301–317. vi2008. View Article : Google Scholar : PubMed/NCBI
|
|
2
|
Zhang H: Endocrine-related cancer.
Encyclopedia of Cancer. Schwab M: 2nd edition. Springer-Verlag;
Heidelberg: pp. 435–439. 2008
|
|
3
|
Shang Y: Molecular mechanisms of oestrogen
and SERMs in endometrial carcinogenesis. Nat Rev Cancer. 6:360–368.
2006. View
Article : Google Scholar : PubMed/NCBI
|
|
4
|
Pietras RJ, Levin ER and Szego CM:
Estrogen receptors and cell signaling. Science. 310:51–53. 2005.
View Article : Google Scholar : PubMed/NCBI
|
|
5
|
Shao W and Brown M: Advances in estrogen
receptor biology: prospects for improvements in targeted breast
cancer therapy. Breast Cancer Res. 6:39–52. 2004. View Article : Google Scholar : PubMed/NCBI
|
|
6
|
O'Lone R, Frith MC, Karlsson EK and Hansen
U: Genomic targets of nuclear estrogen receptors. Mol Endocrinol.
18:1859–1875. 2004. View Article : Google Scholar
|
|
7
|
Bjornstrom L and Sjoberg M: Mechanisms of
estrogen receptor signaling: convergence of genomic and non-genomic
actions on target genes. Mol Endocrinol. 19:833–842. 2005.
View Article : Google Scholar : PubMed/NCBI
|
|
8
|
Song RX, Zhang Z and Santen RJ: Estrogen
rapid action via protein complex formation involving ERalpha and
Src. Trends Endocrinol Metab. 16:347–353. 2005. View Article : Google Scholar : PubMed/NCBI
|
|
9
|
Losel R and Wehling M: Non-genomic actions
of steroid hormones. Nat Rev Mol Cell Biol. 4:46–56. 2004.
View Article : Google Scholar
|
|
10
|
Mckenna NJ, Lanz RB and O'Malley BW:
Nuclear receptor coregulators: cellular and molecular biology.
Endocr Rev. 20:321–344. 1999.PubMed/NCBI
|
|
11
|
Hall JM and Mcdonnell DP: Coregulators in
nuclear estrogen receptor action: from concept to therapeutic
targeting. Mol Interv. 5:343–357. 2005. View Article : Google Scholar : PubMed/NCBI
|
|
12
|
Barnes CJ, Vadlamudi RK and Kumar R: Novel
estrogen receptor coregulators and signaling molecules in human
diseases. Cell Mol Life Sci. 61:281–291. 2004. View Article : Google Scholar : PubMed/NCBI
|
|
13
|
Han SJ, Demayo FJ, Xu J, Tsai SY, Tsai MJ
and O'Malley BW: Steroid receptor coactivator (SRC)-1 and SRC-3
differentially modulate tissue-specific activation functions of the
progesterone receptor. Mol Endocrinol. 20:45–55. 2006. View Article : Google Scholar : PubMed/NCBI
|
|
14
|
O'Malley BW: Coregulators: from whence
came these ‘master genes’. Mol Endocrinol. 21:1009–1013.
2007.PubMed/NCBI
|
|
15
|
Sakaguchi H, Fujimto J and Sun WS:
Clinical implications of steroid receptor coactivator (SRC)-3 in
uterine endometrial cancers. J Steroid Biochem Mol Biol.
104:237–240. 2007. View Article : Google Scholar : PubMed/NCBI
|
|
16
|
Lanard DM, Lanz RB and O'Malhy BW: Nuclear
receptor coregulators and human disease. Endocr Rev. 28:575–587.
2007. View Article : Google Scholar : PubMed/NCBI
|
|
17
|
Gururaj AE, Singh RR and Rayala SK: MTA1,
a transcriptional activator of breast cancer amplified sequence 3.
Proc Natl Acad Sci USA. 103:6670–6675. 2006. View Article : Google Scholar : PubMed/NCBI
|
|
18
|
Webb P, Valentine C and Nguyen P: ER beta
binds N-CoR in the presence of estrogens via an LXXLL-like motif in
the N-CoR C-terminus. Nucl Recept. 1:42003. View Article : Google Scholar : PubMed/NCBI
|
|
19
|
Mishra SK, Balasenthil S and Ngnyen D:
Cloning and functional characterization of PELP1/MNAR promoter.
Gene. 330:115–122. 2004. View Article : Google Scholar : PubMed/NCBI
|
|
20
|
Nair SS, Nair BC, Cortez V, Chakravarty D,
Metzger E, Schüle R, Brann DW, Tekmal RR and Vadlamudi RK: PELP1 is
a reader of histone H3 methylation that facilitates oestrogen
receptor-alpha target gene activation by regulating lysine
demethylase 1 specificity. EMBO Rep. 11:438–444. 2010. View Article : Google Scholar : PubMed/NCBI
|
|
21
|
Cheskis BJ, Greger J, Cooch N, et al: MNAR
plays an important role in ERα activation of Src/MAPK and PI3K/Akt
signaling pathways. Steroids. 73:901–905. 2008.
|
|
22
|
Rajhans R and Vadlamudi RK: Comprehensive
analysis of recent biochemical and biologic findings regarding a
newly discovered protein-PELP1/MNAR. Clin Exp Metastasis. 23:1–7.
2006. View Article : Google Scholar : PubMed/NCBI
|
|
23
|
Vadlamudi RK and Kumar R: Functional and
biological properties of the nuclear receptor coregulator
PELP1/MNAR. Nucl Recept Signal. 5:e0042007.PubMed/NCBI
|
|
24
|
Nair SS, Guo Z, Mueller JM, et al:
PELP1/MNAR enhances androgen receptor functions through LIM-only
coactivator FHL2. Mol Endocrinol. 21:613–624. 2007.PubMed/NCBI
|
|
25
|
Rajhans R, Nair S, Holden AH, Kumar R,
Tekmal RR and Vadlamudi RK: Oncogenic potential of the nuclear
receptor coregulator proline-, glutamic acid-, leucine-rich protein
1/modulator of the nongenomic actions of the estrogen receptor.
Cancer Res. 67:5505–5512. 2007. View Article : Google Scholar : PubMed/NCBI
|
|
26
|
Habashy HO, Powe DG, Rakha EA, et al: The
prognostic significance of PELP1 expression in invasive breast
cancer with emphasis on the ER-positive luminal-like subtype.
Breast Cancer Res Treat. 120:603–612. 2010. View Article : Google Scholar : PubMed/NCBI
|
|
27
|
Vadlamudi RK, Balasenthil S, Broaddus RR,
Gustafsson JA and Kumar R: Deregulation of estrogen receptor
coactivator proline-, glutamic acid-, and leucine-rich
protein-1/modulator of nongenomic activity of estrogen receptor in
human endometrial tumors. Clin Endocrinol Metab. 89:6130–6138.
2004. View Article : Google Scholar : PubMed/NCBI
|
|
28
|
Dimple C, Nair SS, Rajhans R, et al: Role
of PELP1/MNAR signaling in ovarian tumorigenesis. Cancer Res.
68:4902–4909. 2008. View Article : Google Scholar : PubMed/NCBI
|
|
29
|
O'Malley BW and Kumar R: Nuclear receptor
coregulators in cancer biology. Cancer Res. 69:8217–8222. 2009.
View Article : Google Scholar
|
|
30
|
Chakravarty D, Tekmal RR and Vadlamudi RK:
PELP1: a novel therapeutic target for hormonal cancers. IUBMB Life.
62:163–169. 2010.
|
|
31
|
Roy S, Chakravarty D, Cortez V, De
Mukhopadhyay K, Bandyopadhyay A, Ahn JM, Raj GV, Tekmal RR, Sun L
and Vadlamudi RK: Significance of PELP1 in ER-negative breast
cancer metastasis. Mol Cancer Res. 10:25–33. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
32
|
Balasenthil S and Vadlamudi RK: Functional
interactions between the estrogen receptor coactivator PELP1/MNAR
and retinoblastoma protein. J Biol Chem. 278:22119–22127. 2003.
View Article : Google Scholar : PubMed/NCBI
|
|
33
|
Nair BC, Nair SS, Chakravarty D, et al:
Cyclin-dependent kinase-mediated phosphorylation plays a critical
role in the oncogenic functions of PELP1. Cancer Res. 70:7166–7175.
2010. View Article : Google Scholar : PubMed/NCBI
|
|
34
|
Chakravarty D, Roy SS, Babu CR, Dandamudi
R, Curiel TJ, Vivas-Mejia P, Lopez-Berestein G, Sood AK and
Vadlamudi RK: Therapeutic targeting of PELP1 prevents ovarian
cancer growth and metastasis. Clin Cancer Res. 17:2250–2259. 2011.
View Article : Google Scholar : PubMed/NCBI
|
|
35
|
Egeblad M and Werb Z: New functions for
the matrix metalloproteinases in cancer progression. Nat Rev
Cancer. 2:161–174. 2002. View
Article : Google Scholar : PubMed/NCBI
|
